NON SMALL CELL LUNG CANCER

This is the first study in people for a new drug called KK2269. It aims to find a safe dose and see how well the body tolerates it. The study will test KK2269 alone in people with various advanced solid tumors, and also test it combined with a standard chemotherapy drug (docetaxe…

This study is testing whether a combination of a single chemotherapy drug and an immunotherapy drug (pembrolizumab) is safe and effective for people with advanced non-small cell lung cancer who are too frail for standard, more intensive treatments. It aims to help patients who sp…

This early-stage trial is testing whether specially modified immune cells, taken from a patient's own tumor, can help fight advanced lung cancer when given alongside the drug nivolumab. The study is for adults with specific genetic changes in their lung cancer who have already tr…

This early-stage trial is testing a new drug called BG-60366 in people with advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. The drug is designed to find and break down the faulty protein that drives this type of cancer. Researchers …

This study is testing whether a targeted drug called trastuzumab deruxtecan can shrink tumors in people with a specific type of lung cancer (HER2-positive) before they have surgery to remove them. The goal is to see if giving the drug first makes the surgery more effective by kil…

This study aims to find out if a highly focused, non-surgical radiation treatment is better than a limited surgery for people with early-stage lung cancer who are at high risk for complications from major surgery. It will compare survival rates over three years between patients r…

This study compares a new targeted drug called telisotuzumab vedotin against standard chemotherapy (docetaxel) for adults with advanced non-small cell lung cancer that has worsened after previous treatment. The trial aims to see if the new drug helps patients live longer without …

This early-stage study is testing a new drug called PRTH-101, both alone and combined with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors. The main goals are to find a safe dose, see how the body processes the drug, and check for ear…

This study is testing a new combination of two existing drugs, lorlatinib and ramucirumab, for people with advanced lung cancer that has a specific genetic change called ALK. The main goals are to find the safest dose of the drug combination and to see how well it works at contro…

This study is testing the safety and initial effectiveness of a new two-drug combination (YL201 plus ivonescimab) for people with advanced solid tumors, including specific types of lung cancer. The main goals are to find the safest dose and see if the treatment can shrink tumors.…

This early-stage study aims to find a safe and effective dose when combining two drugs (osimertinib and carotuximab) for people with advanced lung cancer that has a specific genetic change (EGFR mutation). Researchers will enroll 60 adults whose cancer has progressed despite prev…

This study is testing a new drug called STX-721/PFL-721 for people with advanced non-small cell lung cancer that has specific genetic mutations (EGFR or HER2 exon 20 insertions). The trial aims to find the safest and most effective dose while checking if the drug can shrink tumor…

This study is for adults with early-stage non-small cell lung cancer who are planning to have surgery. Researchers want to see if a three-drug combination (an immunotherapy drug plus chemotherapy plus a third new drug) works better than just the immunotherapy plus chemotherapy. T…

This study is testing whether an experimental drug called zelenectide pevedotin can help control advanced lung cancer that has a specific genetic feature (NECTIN4 amplification) and has stopped responding to other treatments. It will involve about 73 people with advanced non-smal…

This study is testing if taking a lower dose of the targeted lung cancer drug osimertinib every other day is still effective and possibly easier for patients to tolerate. It is for adults with a specific type of advanced lung cancer (EGFR-positive NSCLC) who have not had prior tr…

This study is testing a combination of two new drugs, called BNT326 and BNT327, for people with advanced non-small cell lung cancer (NSCLC). The main goals are to find safe doses and see if the combination can help shrink tumors or control the cancer's growth. It will enroll abou…

This study is testing the safety and effectiveness of an investigational drug called telisotuzumab vedotin for adults with a specific type of advanced non-small cell lung cancer (NSCLC). The cancer must have a biomarker called c-Met overexpression and must have worsened after pri…

This early-stage trial is testing a new drug called BBO-11818 in people with advanced cancers that have specific KRAS gene mutations. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like lung, pancreatic, and colorectal cancer. Participants wil…

This study is testing whether closely monitoring and proactively managing heart health during intensive lung cancer treatment helps patients live longer and experience fewer serious heart problems. It will involve over 500 adults with advanced lung cancer who are receiving combin…

This study is testing whether a new oral drug called daraxonrasib works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific genetic change (RAS mutation) and has stopped responding to initial treatments. About 420 …

This early-stage trial tests whether a patient's own immune cells can be genetically modified to recognize and attack their cancer. The study is for adults with advanced cancers that have spread and express a specific marker called NY-ESO-1. Researchers will first find the safest…

This study is testing several new combinations of immunotherapy and chemotherapy drugs for people with early-stage, operable lung cancer. The goal is to see if giving these drugs before surgery (to shrink the tumor) and after surgery (to prevent the cancer from coming back) is sa…

This is an early-stage study testing a new drug called BL-M24D1 in patients with advanced non-small cell lung cancer and other solid tumors. The main goals are to find a safe dose, check how the body processes the drug, and look for early signs that it might help control the canc…

This study is testing a combination of three treatments—an immunotherapy drug (atezolizumab), a new immune-stimulating drug (BDB001), and targeted radiation—to see if they can better control advanced solid tumors. It is enrolling 247 adults with specific advanced cancers, includi…

This study aims to understand how well the lung cancer drug osimertinib works for patients in real-world Spanish hospitals, outside of controlled clinical trials. It will follow 500 adults with a specific genetic type of non-small cell lung cancer who are already being treated wi…

This is an early-stage trial testing a new drug called LY3962673 in people with advanced pancreatic, lung, or colorectal cancer that has a specific genetic change called KRAS G12D. The main goals are to find a safe dose and see if the drug, given alone or with other chemotherapie…

This is the first study in people to test a new drug called HMBD-501 for advanced cancers that have a specific marker called HER3 and have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can help shrink or control tumors in pa…

This early-stage study aims to find a safe and effective dose of a new drug called AZD6750, which is designed to boost the immune system to fight cancer. It will test the drug alone and combined with other cancer treatments in about 60 adults with advanced or spreading solid tumo…

This study is testing two different dosing schedules for a new, injectable form of an immunotherapy drug (nivolumab) given under the skin. It is combined with another immunotherapy drug (ipilimumab) and standard chemotherapy. The goal is to see how the body processes the drugs an…

This study is testing whether adding radiation therapy after chemotherapy, immunotherapy, and surgery helps patients with stage III non-small cell lung cancer who still have some cancer cells left. It will compare survival and cancer control between patients who receive the extra…

This study looks at the safety of giving a second, very precise radiation treatment to patients whose lung cancer has returned in the same spot after an initial radiation treatment. It involves 150 patients in Italy who cannot have surgery. The goal is to understand if this secon…

This study is testing whether two experimental drugs, DZD9008 and AZD4205, are safe and can help control advanced non-small cell lung cancer in patients with specific genetic changes (EGFR mutations). It is for people whose cancer has continued to grow despite receiving standard …

This study is testing if adding precise, high-dose radiation to standard drug treatment can better control advanced lung cancer that has started to spread to a few new spots. It will compare this combined approach against switching to new drugs alone in 320 patients. The goal is …

This study is testing if a blood test can help doctors make better treatment decisions for people with advanced lung cancer. The test looks for tiny bits of cancer DNA in the blood. If the DNA is still found after 6 weeks of standard immunotherapy, the study will see if adding ch…

This study is testing a new, more precise way to deliver radiation to brain tumors that have spread from lung cancer. It uses real-time MRI scans to guide the radiation beam very accurately, allowing doctors to remove the standard safety margin around the tumor. The goal is to se…

This study tests whether combining targeted radiation with immunotherapy drugs before surgery can better eliminate lung cancer tumors. It involves 30 adults with stage II-III non-small cell lung cancer who are eligible for surgery. The goal is to see if this combination treatment…

This study is testing whether giving specific, personalized drug treatments before and after surgery can better control early-stage lung cancer. It is for people whose tumors have certain genetic markers. The goal is to see if these targeted approaches shrink tumors more effectiv…

This study is testing a two-part treatment for advanced non-small cell lung cancer that has started to grow again after initial immunotherapy. It combines a drug (toripalimab) that helps the immune system attack cancer with a procedure (cryoablation) that freezes and destroys a f…

This study is testing whether adding a specific gut bacteria supplement (EXL01) to an immunotherapy drug (nivolumab) can help control advanced lung cancer that has stopped responding to standard treatments. It will involve about 21 patients who have already tried and progressed o…

This study is testing whether adding new experimental drugs to standard immunotherapy and chemotherapy works better for people with advanced lung cancer that has spread. Researchers want to see if these combinations can shrink tumors more effectively and are safe for patients. Th…

This study is testing whether combining two immunotherapy drugs (ES102 and toripalimab) can help control advanced non-small cell lung cancer in patients whose previous treatments have stopped working. The trial will enroll 40 adults with specific types of lung cancer to see how w…

This program provides access to an experimental drug called zidesamtinib for adults with advanced, ROS1-positive cancers, primarily lung cancer. It is for patients who have already tried at least one other targeted therapy and have no other satisfactory treatment options availabl…

This study is testing a three-part treatment for stage III non-small cell lung cancer that cannot initially be removed by surgery. The goal is to see if combining a specialized form of radiation (SFRT) with an immunotherapy drug (tislelizumab) and standard chemotherapy can shrink…

This study is testing if a new drug called HLX17 works similarly to the established cancer drug Keytruda. It aims to prevent cancer from returning in people who have had surgery for certain lung, skin, or kidney cancers. Researchers will compare how the two drugs are processed by…

This study is testing an oral drug called cabozantinib in people with advanced non-small cell lung cancer that has specific genetic changes (like RET, ROS1, or NTRK fusions). The main goal is to see if the drug can shrink the cancer and stop it from growing. Researchers will also…

This study is testing a new two-drug combination (HLX43 plus serplulimab) given to patients before they have surgery for non-small cell lung cancer. The goal is to see if this treatment can shrink or eliminate the tumor to make surgery more effective. The study will enroll 60 adu…

This global Phase 3 trial is comparing a new drug called firmonertinib against two existing standard treatments for people with advanced non-small cell lung cancer that has specific, less common EGFR genetic mutations. The study aims to see if firmonertinib can better control the…

This study is testing whether giving radiation to the main lung tumor before starting targeted drug therapy can help delay cancer progression in patients with advanced lung cancer that has specific genetic changes. The trial will enroll 34 patients who haven't had previous treatm…

This is the first study in people testing a new cancer drug called MGC026. It aims to find a safe dose and see if the drug can help shrink tumors in adults with advanced solid tumors that have not responded to other treatments. The study will also check how the drug moves through…

This study is testing a new oral drug, S241656, alone and in combination with other cancer therapies. It aims to find a safe and effective dose for adults with advanced cancers, including lung, pancreatic, and colorectal cancers, that have specific genetic mutations like KRAS or …

This study is testing an investigational drug called TQB2102 for people with advanced non-small cell lung cancer that has a specific genetic change (HER2 abnormality) and has stopped responding to standard treatments. The drug is designed to deliver a powerful cancer-killing agen…

This global study is testing whether adding a new investigational drug called BNT327 (pumitamig) to standard chemotherapy works better for people newly diagnosed with advanced non-small cell lung cancer. It will involve about 1,260 participants and has two parts: first to check s…

This study is testing several new combinations of cancer drugs for people with advanced non-small cell lung cancer that has spread. The main goals are to see if these combinations are safe and if they can shrink tumors. The trial will involve about 278 patients across 80 medical …

This study aims to find out if adding a precise, targeted form of radiation to the brain (called stereotactic radiosurgery) to standard drug treatments works better than drugs alone for people whose melanoma or non-small cell lung cancer has spread to the brain. It will enroll 18…

This study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…

This study is testing a new type of personalized cell therapy called OBX-115 in adults with advanced melanoma or non-small cell lung cancer that has progressed after standard treatments. Doctors take a patient's own immune cells from a tumor, genetically engineer them to be more …

This program provides access to an investigational drug called ulixertinib for patients with advanced cancers that have specific genetic changes (MAPK pathway mutations). It is for people who have run out of other treatment options. The drug aims to control the cancer's growth, e…

This study is testing a new oral medication called Alintegimod, given alongside the immunotherapy drugs ipilimumab and nivolumab. It aims to see if this combination is safe and can help control advanced cancers that have spread or returned after other treatments. The study will e…

This is the first human study of LNCB74, a new targeted cancer drug designed to deliver chemotherapy directly to cancer cells. Researchers will test different doses in 145 adults with advanced solid tumors (including ovarian, breast, lung, and other cancers) to find the safest an…

This study is testing a new targeted drug called andamertinib, given alone or with standard chemotherapy, for people with advanced non-small cell lung cancer. It is for patients who have a specific, less common type of genetic change (atypical EGFR mutation) and have not yet rece…

This early-stage study is testing whether a new drug called ANK-101, when combined with standard immunotherapy, can help control advanced non-small cell lung cancer. It will enroll 60 participants, including both patients who have already tried immunotherapy and those who haven't…

This study is testing whether adding a new drug called valemetostat to a standard immunotherapy (pembrolizumab) works better than the standard drug alone for people with advanced non-small cell lung cancer. It is for adults who have not had prior treatment for their advanced canc…

This early study is testing the safety of a new cell therapy for adults with advanced lung cancer that has stopped responding to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back into th…

This study is testing whether adding targeted radiation to standard targeted drug therapy helps control advanced lung cancer for longer. It's for patients whose cancer has spread to only a few sites and has specific genetic mutations. Researchers will compare how long the cancer …

This study compares a new two-drug combination (divarasib + pembrolizumab) against standard chemotherapy for adults with advanced lung cancer that has a specific KRAS G12C mutation and hasn't been treated before. The goal is to see if the new combination helps patients live longe…

This study is testing whether adding electroacupuncture (a form of acupuncture using mild electrical stimulation) to standard immunotherapy (PD-1 inhibitors) helps people with advanced non-small cell lung cancer live longer without their cancer getting worse. It will involve 120 …

This study is testing whether using focused ultrasound to temporarily open the protective blood-brain barrier can help standard immunotherapy drugs better reach and treat lung cancer that has spread to the brain. It will compare this new approach to standard treatment alone in ab…

This is the first study in people to test a new drug called DZD6008 for advanced non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutations). The main goals are to find a safe dose and see if the drug can shrink tumors. It will enroll about 140 adults wh…

This study is testing a combination of three drugs for people with non-small cell lung cancer that has spread to the brain and who have not yet received treatment for their advanced cancer. The goal is to see how well this three-drug combo can shrink the tumors in the brain. The …

This study is testing whether adding an experimental drug called nelmastobart to standard chemotherapy (docetaxel) can help control advanced lung cancer. It's for patients whose cancer has continued to grow despite previous treatments like platinum-based chemotherapy or immunothe…

This program provides access to an investigational drug called neladalkib for patients with advanced ALK-positive cancers, including lung cancer. It is for adults who have tried other treatments without success and cannot join a formal clinical trial. The goal is to offer a poten…

This early-stage study is testing a new experimental drug called BGB-43395, both alone and in combination with other cancer medications, for people with advanced hormone-positive breast cancer and other solid tumors. The main goals are to find safe dosage levels and see if the dr…

This early-stage trial is testing a new type of cell therapy for people with advanced lung cancer that has spread and no longer responds to standard treatments. The therapy uses specially modified 'natural killer' immune cells designed to recognize and attack cancer cells that ha…

This is a very early, first-in-human study to test the safety and find the right dose of a new radioactive drug called 177Lu-RAD204. It is for adults with advanced solid tumors (like lung, breast, or skin cancer) that have spread and have stopped responding to standard treatments…

This is the first human study of an experimental drug called OCT-598 for people with advanced solid tumors that have stopped responding to standard treatments. Researchers will test increasing doses to find the safest and most effective amount, both when given alone and when comb…

This early-stage study is testing a new oral drug called CP-383 in people with advanced solid tumors that have spread or returned. The main goals are to find a safe dose and see if the drug can slow or stop cancer growth. It is for patients who have run out of standard treatment …

This study is testing whether adding a traditional Chinese herbal formula (HuGuXiaoJiTang) to standard immunotherapy helps control non-small cell lung cancer that has spread to the bones. About 82 participants will be randomly assigned to receive either the herbal medicine or a p…

This study is testing whether adding a new drug called Sigvotatug Vedotin to standard immunotherapy works better for advanced non-small cell lung cancer. It will involve 714 people with high levels of a specific protein (PD-L1) in their cancer cells. Half will get the new combina…

This international trial is for people with a certain stage of non-small cell lung cancer that can be surgically removed. It tests whether adding a year of immunotherapy (durvalumab) after surgery provides extra benefit, compared to just observation, for patients who have already…

This study is testing a new type of cancer drug that delivers radiation directly to tumors by targeting a protein called Nectin-4. It aims to find a safe and effective dose for patients with advanced solid cancers who have already tried other treatments. The trial will first dete…

This study is testing whether a new drug called izalontamab brengitecan works better than standard chemotherapy for people with advanced lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to their current targeted therapy. The trial will inv…

This study is testing whether combining two drugs, Envafolimab and Lenvatinib, can help control advanced cancers like lung, kidney, and liver cancer that have progressed after standard treatments. The goal is to see if this combination is safe and can shrink tumors better than cu…

This study is testing if an existing cancer drug called zanidatamab can help control several different types of advanced cancer. It is for adults with lung, colon, head & neck, uterine, or sarcoma cancers that have stopped responding to standard treatments and have a specific cha…

This study is for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has started growing again after their first targeted treatment. Researchers want to see if giving a higher dose of the drug furmonertinib, or combining a stand…

This study is testing a shorter, more focused form of radiation therapy for people with lung tumors. It aims to see how well this treatment controls cancer growth and what side effects occur. Participants will receive high-dose radiation over 1-2 weeks instead of the usual severa…

This study is testing a new oral drug called TNG260, given alone and with the immunotherapy pembrolizumab, for people with advanced solid tumors that have a specific genetic change (STK11 mutation). The main goals are to find a safe and effective dose and to see if the treatment …

This study is testing whether adding an experimental drug called pumitamig to standard chemotherapy helps control advanced non-small cell lung cancer that has worsened after initial treatment. It will involve about 60 people with this type of cancer. The first part checks the saf…

This study is testing if using two different immune-boosting drugs together with chemotherapy works better than the current standard of one immune drug plus chemo. It focuses on patients with advanced non-small cell lung cancer whose tumors lack a specific marker called PD-L1. Re…

This study is testing a new combination of drugs for people with a specific type of advanced lung cancer that has spread. The goal is to see if adding a short course of a drug called mirdametinib to standard chemotherapy and immunotherapy is safe and more effective at controlling…

This study aims to understand the safety and side effects of the drug sotorasib when used in real-world medical settings in China. It will follow about 115 Chinese adults with a specific type of advanced lung cancer who have already tried at least one other treatment. The main go…

This is the first study in people to test a new drug called BBO-8520 for advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to find a safe dose and see if the drug can help shrink tumors. The study will test BBO-8520 alone …

This early-stage study is testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific genetic change called KRAS G12D. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to recognize and attack canc…

This global Phase 3 trial is testing whether a new drug called rilvegostomig works better than the current standard treatment when combined with chemotherapy for advanced squamous lung cancer. The study will involve about 880 patients whose cancer has spread and who haven't recei…

This is the first human study of an experimental oral drug called AOH1996 for patients with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand how the body processes the drug. Researchers will enrol…

This study is testing whether it is safe to combine a new targeted drug called tarlatamab with standard radiation therapy. It is for adults with advanced cancers that have a specific protein called DLL3, including certain lung cancers, melanoma, and others. The main goal is to se…

This study is testing whether adding a new oral drug called tulmimetostat to an existing immunotherapy (pembrolizumab) can help control advanced non-small cell lung cancer. It is for patients whose cancer has continued to grow despite previous treatments that included immunothera…

This study is testing whether a new two-drug combination (IN10018 plus D-1553) works better than the current standard first treatment for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The trial will involve about 400 adults w…

This study is testing a new two-drug combination (GEN-725 plus Dositinib) for people with advanced lung cancer that has a specific genetic change (EGFR mutation). It aims to see if the treatment is safe and if it can shrink tumors, including those that have spread to the brain. T…

This study is testing whether a daily pill called sunvozertinib can help prevent lung cancer from returning in people who have had surgery to remove their tumor. It will compare the pill to a placebo in 360 adults with a specific type of non-small cell lung cancer and certain gen…

This large, late-stage trial is testing whether adding a new drug called SHR-A2009 to the standard treatment (aumolertinib) works better for people with a specific type of advanced lung cancer. It will involve 576 adults who have not yet received treatment for their advanced canc…

This study is testing an oral drug called pyrotinib as the first treatment for people with advanced non-small cell lung cancer that has specific HER2 genetic changes. The goal is to see if the drug is safe and effective at shrinking tumors and controlling the cancer. Researchers …

This study tests whether a new drug called NVL-655 works better than the current standard treatment (alectinib) for people with advanced ALK-positive lung cancer who haven't had treatment before. About 450 participants will be randomly assigned to receive either the new drug or t…

This study is testing a new oral drug called TNG456, both alone and combined with another cancer drug (abemaciclib), in people with advanced solid tumors that have a specific genetic change called MTAP loss. The main goals are to find safe doses and see if the treatment can shrin…

This study is for people with early-stage non-small cell lung cancer who have finished their standard treatment. It uses a special blood test to look for tiny leftover cancer signals. If the test is positive, participants receive a drug called durvalumab to try to clear these sig…

This study is testing an experimental drug called YL202 in people with advanced solid tumors, including lung, colorectal, and cervical cancer, that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors and control the disease, and to unders…

This study is testing an experimental drug called DRP-104 for people with a specific type of advanced non-small cell lung cancer that has continued to grow despite standard chemotherapy and immunotherapy. The drug works by blocking a nutrient called glutamine that some cancer cel…

This study is testing whether a daily pill called zongertinib can help people with early-stage lung cancer live longer without their cancer returning after surgery. It compares the pill to standard treatments for up to 3 years in 400 adults whose cancer has a specific HER2 gene c…

This study is testing whether a new drug called volrustomig, when given alongside standard chemotherapy, is safe and can help control advanced non-small cell lung cancer. It will involve about 180 people whose cancer has spread and who have not yet received treatment for the adva…

This study is testing whether a supplement called Urolithin A can improve how the immune system responds to cancer immunotherapy drugs. Researchers will compare 45 patients with newly diagnosed solid tumors who take either the supplement or a placebo while receiving standard immu…

This study is testing whether a new drug called SKB264 works better than standard chemotherapy when combined with pembrolizumab immunotherapy for advanced non-small cell lung cancer. It's specifically for patients whose tumors test negative for PD-L1, a marker that often predicts…

This study is testing the safety of adding a wearable medical device, called Tumor Treating Fields (TTFields), to the standard treatment for a specific type of advanced lung cancer. The device uses electric fields that may help stop cancer cells from growing. Researchers want to …

This early-stage study is testing a new radioactive drug treatment for people with advanced solid tumors that have stopped responding to standard therapies. Researchers will first use a special imaging scan to see if patients' tumors are likely to respond, then give the radioacti…

This is a first-in-human study to test the safety and find the right dose of a new oral drug, OKN4395, for people with advanced solid tumors. The trial will give the drug alone and combined with an existing immunotherapy (pembrolizumab) to about 166 participants with cancers like…

This study is testing a combination of chemotherapy, immunotherapy, and radiation for veterans with a specific type of advanced lung cancer that cannot be removed by surgery. The goal is to see if this three-part treatment is safe and effective at controlling the cancer and keepi…

This early-stage study is testing FT836, a new type of 'off-the-shelf' CAR T-cell therapy, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how well the body tolerates FT836, which is given al…

This study is testing a new oral medication called NEO212 for adults with specific aggressive brain tumors (like glioblastoma) or brain metastases from other cancers. The main goals are to find a safe and effective dose, see how the body processes the drug, and check if it can he…

This study is for people with stage III non-small cell lung cancer that can be removed with surgery. It tests if adding a drug called envafolimab to standard chemotherapy, given both before and after surgery, works better and is safe compared to chemotherapy alone. The goal is to…

This study is testing whether a targeted drug called lazertinib, given alone or with standard chemotherapy before surgery, can better shrink tumors in people with early-stage lung cancer that has a specific genetic change (EGFR mutation). The goal is to see if this pre-surgery tr…

This study is testing if adding a precise, high-dose radiation treatment to liver tumors helps standard immunotherapy drugs work better for people with advanced lung cancer that has spread to the liver. It will compare the standard drug treatment alone to the drug treatment plus …

This study is testing whether adding a new immunotherapy drug called QL1706 to standard chemotherapy helps people with a certain type of lung cancer that can be removed by surgery. About 30 participants will receive the drug combination before their operation, aiming to shrink th…

This study is testing a new combination of two drugs, DZD6008 and sunvozertinib, for people with advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. The main goals are to find a safe dose, understand the side effects, and see if the com…

This early-stage study is testing a new oral drug called VMD-928, both by itself and combined with an existing immunotherapy (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have progressed despite available treatments. The main goals are to find safe…

This early-stage study is testing a new oral drug called VS-7375, which is designed to block a specific cancer-driving mutation known as KRAS G12D. Researchers will give the drug alone and in combination with other cancer therapies to adults with advanced solid tumors, including …

This study is testing a new two-drug combination (BL-B01D1 + SI-B003) for people with advanced lung cancer or throat cancer that has spread. The main goals are to see if the treatment can shrink tumors and to determine the safest and most effective dose. It will involve about 121…

This is a first-in-human study testing a new personalized cell therapy called NT-175. It is for adults with advanced solid cancers (like lung, colorectal, or breast cancer) that have spread and have a specific genetic mutation (TP53 R175H). The main goals are to find a safe dose …

This study is testing a new drug called YL202, given alongside other cancer treatments, to see if it is safe and effective for people with advanced solid tumors like breast or lung cancer. The main goals are to find the safest dose and see if the treatment helps shrink tumors. It…

This study is testing a new, experimental drug called GI-101 in people with advanced cancers that have spread. The main goals are to find a safe dose and see if the drug, given alone or with other approved cancer medicines, can help shrink tumors. The trial will enroll about 317 …

This is the first human study of an experimental drug called PT0511 for people with advanced solid tumors that have specific KRAS genetic changes. The main goals are to find safe doses and see how the body processes the drug, both alone and combined with another cancer medication…

This study is testing a new combination of two drugs, ZG005 and gecacitinib, for people with advanced non-small cell lung cancer whose cancer has grown despite previous immunotherapy. The main goals are to find a safe dose and see if the combination shows early signs of shrinking…

This study is testing a new type of radiation therapy called lattice radiation (LRT) for people with large cancer tumors that have spread to soft tissues. It compares LRT to standard radiation to see which is better at shrinking tumors and attracting immune cells to fight the can…

This is the first human study of an experimental cancer drug called CTX-8371. It aims to find safe doses and see how the body handles the drug in 73 patients with advanced cancers that have stopped responding to standard treatments. The study will test different dose levels to de…

This is the first-ever study in people for a new drug called EPI-326. It aims to find a safe dose and see how the body handles the drug in patients with advanced lung cancer (with a specific genetic change called EGFR mutation) or advanced head and neck cancer. The main goal is t…

This study is testing whether adding a new drug called domvanalimab to an existing immunotherapy (durvalumab) works better than durvalumab alone for people with advanced, inoperable lung cancer. The goal is to help control the cancer and prevent it from growing or spreading after…

This study is testing whether an experimental drug called SAR445877 can help control advanced non-small cell lung cancer in patients whose cancer has continued to grow despite previous immunotherapy treatment. The trial will enroll about 29 adults who have exhausted other standar…

This is an early-stage safety study for a new drug called ANK-101, which is injected directly into tumors. It aims to find a safe dose for people with advanced solid cancers that have stopped responding to standard treatments. The study will test the drug alone in different types…

This study is testing whether a drug called BIO 300 can help protect the lungs of patients who have both early-stage lung cancer and a separate lung scarring disease (interstitial lung disease) when they receive radiation therapy. The main goal is to see if BIO 300 can prevent se…

This study is testing whether adding a new oral drug called vebreltinib to standard chemotherapy works better than chemotherapy alone for people with advanced non-squamous non-small cell lung cancer (NSCLC) who have a specific genetic feature called MET-positive. The trial aims t…

This study is testing a new drug, AMG 193, alone and in combination with other cancer therapies for adults with advanced lung or chest tumors that have a specific genetic change called MTAP-deletion. The main goals are to find the safest and most effective dose and to see how wel…

This study compares two targeted drugs for advanced lung cancer with a specific genetic change called ROS1. About 138 patients who haven't tried this type of treatment will receive either the experimental drug taletrectinib or the standard drug crizotinib. Researchers want to see…

This study is testing how well the immunotherapy drug pembrolizumab, with or without chemotherapy, works for Black patients with advanced non-small cell lung cancer. It aims to see how long patients live and how long the cancer stays controlled, while also looking for markers in …

This study is testing a new drug called GV20-0251 for adults with advanced solid tumor cancers that have progressed despite standard treatments. The first part aims to find a safe dose, and the second part will see how well the drug works against several types of cancer, includin…

This is the first study in people to test the safety and behavior of a new drug called azirkitug. It will be given alone and in combination with two other cancer drugs to adults with advanced solid tumors, including lung and head and neck cancers, who have already tried standard …

This study is testing how well and how safely the drug sunvozertinib works for adults with advanced non-small cell lung cancer. It is for people who have not had any prior cancer treatment and whose cancer has specific, less common genetic changes (EGFR mutations). The main goal …

This study compares a new two-drug combination (trastuzumab deruxtecan plus pembrolizumab) against standard chemotherapy plus pembrolizumab for people with advanced non-small cell lung cancer that has spread and has specific tumor markers. It aims to see if the new combination ca…

This study is testing whether combining three existing cancer drugs—carboplatin, paclitaxel, and ramucirumab—can shrink tumors or slow their growth in people with advanced non-small cell lung cancer whose disease has worsened on standard maintenance therapy. It will involve about…

This study is testing if a new two-drug combination works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The new treatment pairs a targeted drug (calderasib) with an immunotherapy (pembrol…

This study is testing whether regularly checking for cancer DNA in the blood (a 'liquid biopsy') can help doctors better manage treatment for advanced colorectal or lung cancer. Patients will have their tumor's genetics analyzed, and a team of experts will recommend a treatment p…

This study is testing a new drug called LY4050784 for people with advanced solid tumors that have a specific genetic change called a SMARCA4/BRG1 alteration. The main goals are to find a safe dose of the drug, given alone or with other cancer treatments, and to see if it helps sh…

This study is testing an experimental drug called zanidatamab for people with advanced cancers that have a specific marker called HER2 and have stopped responding to prior treatments. It will enroll about 200 adults with various cancers including breast, lung, stomach, and ovaria…

This study is testing a new drug called STK-012 for people with advanced non-small cell lung cancer (NSCLC). The main goal is to see if adding STK-012 to standard chemotherapy and immunotherapy helps shrink tumors better than the standard treatment alone. The trial is currently e…

This study is testing a new combination of two immunotherapy drugs, HLX43 and serplulimab, for people with advanced solid tumors or a specific type of lung cancer. The main goals are to find a safe and effective dose and to see if the treatment can shrink tumors. It will enroll a…

This study is for people with a certain type of lung cancer (non-small cell) that was removed by surgery but still showed some cancer cells. It tests if adding a new drug called sacituzumab tirumotecan to the standard drug pembrolizumab works better at keeping the cancer from com…

This study is testing whether adding a new drug called SHR-A2102 to other cancer treatments before and after surgery helps people with operable non-small cell lung cancer. Researchers want to see if this combination can better eliminate cancer cells and prevent the cancer from co…

This study aims to make standard radiation therapy more effective for non-small cell lung cancer. Researchers are testing new drugs designed to block cancer cells' ability to repair the DNA damage caused by radiation, which could help kill more cancer cells. The trial will find t…

This study is testing a new combination of two drugs, called SI-B001 and SI-B003, for people with advanced non-small cell lung cancer that has spread. The first part aims to find a safe dose, and the second part will see how well the drug combo works, either alone or with standar…

This early-stage study is testing a new oral drug called CGT4255 in adults with advanced solid tumors that have specific genetic changes (ERBB2 alterations or HER2 overexpression). The main goals are to find a safe dose and see if the drug can shrink tumors, including those that …

This study aims to learn more about how well and how safely a cancer drug called cemiplimab (Libtayo) works for people with advanced non-small cell lung cancer in everyday medical practice. It will follow about 500 patients in Europe who are already prescribed this drug by their …

This study is testing if adding a very low dose of radiation to the liver can make standard immunotherapy work better for people with lung cancer or melanoma that has spread to the liver. It is for patients already planning to receive immunotherapy. The goal is to see if this com…

This study is testing whether new drug combinations work better than the current standard treatment for advanced non-small cell lung cancer. It will involve 675 people with a specific type of lung cancer that has spread and has high levels of a protein called PD-L1. Participants …

This is the first human trial of an experimental drug called BNT116 for people with advanced non-small cell lung cancer. The main goal is to find safe doses when BNT116 is given alone and when combined with other approved or experimental cancer drugs. The study will enroll about …

This study continues to monitor patients who have already completed previous cancer treatment studies with dabrafenib and/or trametinib. It tracks 100 patients with various cancers including melanoma and lung cancer to understand the long-term safety of these medications. The goa…

This study is observing how well a newer drug called iruplinalkib works for people with advanced ALK-positive lung cancer who have already tried and stopped responding to a standard drug called lorlatinib. It will follow about 20 patients in real-world hospital settings to see ho…

This study is testing a new drug, PF-08634404, when used alongside other cancer medicines in adults with advanced non-small cell lung cancer that has spread. The main goals are to see if the drug combinations are safe and if they can help control the cancer. The study is in early…

This study is testing if a drug called cemiplimab, a type of immunotherapy, can help prevent non-small cell lung cancer from coming back after it has been surgically removed. It is for patients with stage II or IIIA lung cancer who have had surgery but have decided not to get, or…

This study is testing whether adding a specialized type of radiation called spatially fractionated radiotherapy (SFRT) to a patient's standard drug treatment can better control advanced non-small cell lung cancer that has spread to a few new spots. It aims to see if this combinat…

This large, late-stage study is testing if adding a new drug called MK-2870 to a standard treatment helps people with advanced squamous non-small cell lung cancer live longer. About 851 participants will first receive a standard chemotherapy and immunotherapy combination. Then, t…

This study compares two different drug combinations for people with advanced non-small cell lung cancer that has spread. About 1600 participants will receive either a new drug called ivonescimab or the standard drug pembrolizumab, both combined with chemotherapy. The main goals a…

This study is testing if a healthy donor stool transplant (FMT) can help the body fight cancer when given alongside the immunotherapy drug pembrolizumab. It is for people with advanced non-small cell lung cancer where prior immunotherapy has stopped working. The goal is to see if…

This is the first study in people to test a new drug called BL-B01D1. It aims to find a safe dose and see if it can help control advanced cancers that have spread or cannot be removed by surgery. The trial will enroll about 470 adults with various solid tumors, including lung, br…

This is a first-in-human study to test the safety and find the right dose of a new investigational drug called LY4052031 for people with advanced or metastatic solid tumors. The drug is designed to target a specific protein found on many cancer cells, delivering its medicine dire…

This early-stage study is testing a new combination treatment for people with advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation. The treatment combines a personalized vaccine designed to target the cancer's mutation with two existing im…

This study is looking at whether adding surgery or radiation to the primary lung tumor can help people with advanced, EGFR-mutant lung cancer live longer without their cancer getting worse. It is for patients whose cancer has been controlled by a specific combination of drugs. Th…

This study is testing if adding a new drug called SKB264 to the standard treatment (osimertinib) works better for people with a specific type of advanced lung cancer. It will involve 420 adults who have not yet received treatment for their advanced cancer. The main goal is to see…

This study is testing a new targeted drug called divarasib, given alone or with other cancer therapies, for people with advanced non-small cell lung cancer (NSCLC) who have a specific genetic change called KRAS G12C and have not yet received any treatment for their advanced disea…

This study is testing if a more precise form of radiation therapy can control lung tumors while causing fewer breathing-related side effects. It will compare a new, highly targeted adaptive technique against the current standard method in patients with early-stage lung cancer or …

This large study aims to find out if robot-assisted surgery is as good as or better than standard video-assisted surgery for removing early-stage lung cancer. It will enroll over 1,100 patients to compare survival rates, recovery time, pain, and complications between the two surg…

This is the first time researchers are giving the experimental drug ASP5834 to people. The study aims to find a safe dose and check for side effects in adults with advanced solid tumors that have specific changes in a gene called KRAS. Some participants with colorectal cancer wil…

This study is testing whether a new drug called PF-08634404, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab with chemotherapy) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned…

This study is testing a combination of three treatments for a severe form of lung cancer that has spread to the brain and its protective lining. It will involve 30 adults with a specific genetic marker (EGFR mutation) who have not yet received treatment for their advanced cancer.…

This program provides early access to an investigational cancer drug called telisotuzumab adizutecan for people with solid tumors. It is for patients who have no other suitable treatment options and do not qualify for ongoing clinical trials. A doctor must determine if the potent…

This study is testing if adding radiation therapy to standard immunotherapy helps patients with a specific type of advanced lung cancer live longer without their cancer getting worse after surgery. It will involve 60 adults who have had surgery but are at high risk of the cancer …

This study is testing whether adding a special surgical sealant during lung cancer surgery helps patients recover faster. Researchers will compare patients who get the sealant with those who get standard surgery to see if it reduces air leaks, a common complication. The main goal…

This large Phase 3 trial is testing whether a new immunotherapy drug called ivonescimab works better than the current standard drug (pembrolizumab) for people with advanced non-small cell lung cancer that has spread and shows high levels of a specific marker called PD-L1. The stu…

This study is testing an investigational drug called telisotuzumab adizutecan for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) whose cancer has continued to grow despite treatment with a modern targeted therapy. The goal is to see if this …

This study is testing if a capsule drug called anlotinib can help prevent lung cancer from returning in patients who have had surgery. It is for people with non-small cell lung cancer who still had cancer cells present after their initial treatment. The main goal is to see if the…

This large, late-stage trial is testing whether a new immunotherapy drug called gotistobart (ONC-392) can help people live longer than standard chemotherapy for a specific type of advanced lung cancer. It is for adults whose metastatic non-small cell lung cancer has continued to …

This is the first study in people for a new radioactive drug called [225Ac]-FPI-2068. It aims to find a safe dose and see how the drug travels in the body of 70 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check safety…

This is the first study in people to test a new cancer drug called SIM0610. It aims to find a safe dose and see if it can shrink tumors in adults with advanced solid cancers that have stopped responding to standard treatments. The study will enroll 260 people with cancers like lu…

This study is testing whether eating more fermented foods like yogurt, kimchi, and kombucha can help people with rectal or lung cancer. Researchers want to see if this special diet makes standard cancer treatments like chemotherapy and immunotherapy work better. They will also ch…

This study is testing a new surgical technique for early-stage lung cancer. It combines 3D computer planning before surgery with a special fluorescent dye during surgery to help the surgeon see exactly which part of the lung to remove. The goal is to remove only the cancerous seg…

This study aims to determine whether surgery or targeted radiation therapy is more effective for treating early-stage lung cancer. It will follow 444 patients who are eligible for either treatment, tracking their cancer recurrence, survival, and quality of life for up to three ye…

This study is for people with advanced non-small cell lung cancer who have a specific genetic change (EGFR mutation). It tests if adding a second drug (sacituzumab tirumotecan) to their current medication (osimertinib) helps control the cancer better. The decision to add the seco…

This study is testing a new drug called BMS-986340 to see if it is safe and can help control advanced cancers. It will be given alone or combined with two other cancer drugs to about 950 people whose cancers have grown despite standard treatments. The main goal is to find the rig…

This study compares two radiation methods for patients whose cancer has spread to the brain and who are receiving immunotherapy. Researchers want to see if giving smaller radiation doses over several days causes fewer side effects than the standard single-day treatment. The trial…

This is the first human study of an experimental antibody called GNC-077 for people with advanced non-small cell lung cancer and other solid tumors. The main goal is to find a safe dose and understand how the body processes the drug. Researchers will enroll about 20 participants …

This study is testing a new pre-surgery treatment for people with operable non-small cell lung cancer. Before having surgery to remove the tumor, participants receive a combination of two immunotherapy drugs (ipilimumab and nivolumab) along with a short, targeted course of low-do…

This study is for people with advanced non-small cell lung cancer who initially did well on immunotherapy but now show signs of returning disease in their blood. It tests if switching to a new combination of two drugs (Ivonescimab and docetaxel) is better than standard care at ke…

This study is testing whether adding a new drug called calderasib (MK-1084) to an existing immunotherapy (pembrolizumab) works better for people with a specific type of advanced lung cancer. It will involve about 600 adults whose cancer has a KRAS G12C mutation and high levels of…

This is the first human study of an experimental cancer drug called LY4101174. Researchers want to find a safe dose and see if it can help control advanced cancers that have spread or returned after other treatments. The study will enroll about 490 people with various solid tumor…

This study is testing whether a new combination of two investigational drugs, livmoniplimab and budigalimab, plus standard chemotherapy works better and is safer than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung can…

This study is testing a personalized cell therapy for people with metastatic cancer that has not responded to standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to better recognize and attack their specific cancer, and then infus…

This is the first study in people to test a new cancer drug called KIVU-107. The main goal is to find a safe dose and see how well the body handles it. It is for adults with advanced solid tumors that have spread or cannot be removed by surgery and have stopped responding to avai…

This study is testing whether combining a targeted drug (adagrasib) with precise radiation to the brain (stereotactic radiosurgery) can better control lung cancer that has spread to the brain. It is for up to 30 adults with a specific type of advanced lung cancer (KRAS G12C-mutat…

This early-stage study is testing a new oral medicine called PF-07799933, both alone and combined with other drugs, for people with advanced solid tumors that have a specific BRAF gene change and have stopped responding to standard treatments. The main goals are to find a safe do…

This study is for people with advanced non-small cell lung cancer that has started to grow again after their first treatment with immunotherapy and chemotherapy. It compares a new two-part treatment—first a specially engineered virus given by IV, followed by standard chemotherapy…

This is the first study in people of an experimental pill called MRTX1719. It is for adults with advanced solid tumors that have a specific missing gene called MTAP, which is found in some lung cancers, mesothelioma, and other cancers. The main goals are to find a safe dose, see …

This study is testing whether a new drug called BL-B01D1 works better when combined with an existing immunotherapy (PD-1 antibody) to control advanced cancers that have spread. It will involve about 570 adults with non-small cell lung cancer, nasopharyngeal cancer, or other solid…

This study is testing if a new two-drug combination works better than the current standard single drug for people with a specific type of advanced lung cancer. It will involve about 582 adults who have not yet received treatment for their advanced cancer. The main goal is to see …

This early-stage study is testing the safety and initial effectiveness of a personalized cell therapy called GC101 TIL for adults with advanced non-small cell lung cancer. Doctors take a patient's own tumor-fighting immune cells, grow large numbers of them in a lab, and then infu…

This study is testing whether a lower dose of chemotherapy, when combined with immunotherapy, is safer and easier to tolerate for older or frail adults with advanced lung cancer. The main goal is to see if this gentler approach causes fewer severe side effects that would force pa…

This is the first study in people to test a new drug called AU-007 for advanced cancers that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug shows early signs of helping. It will be tested alone and in combination with other…

This early-stage trial is testing a two-part personalized treatment for adults with advanced solid cancers that have spread and contain specific KRAS gene mutations. Doctors take a patient's own immune cells, genetically modify them in a lab to recognize and attack cancer cells w…

This study is testing whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent lung cancer from returning after surgery. It will involve about 868 people whose stage II or III non-small cell lung cancer has been completely rem…

This study is testing a new approach for people with early-stage lung cancer who have had surgery. Researchers are using a special blood test to look for tiny traces of leftover cancer. If the test finds these traces, patients receive a combination of chemotherapy and immunothera…

This study is testing a new type of personalized cell therapy for adults with advanced solid tumors that have come back or spread. The therapy, called Tmod CAR T, is designed to recognize and kill cancer cells while using a built-in safety switch to protect the patient's healthy …

This study is testing a new drug called Rina-S in people whose solid tumor cancers have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug can shrink tumors. It is for people with several types of advanced cancer, including ovarian,…

This study is testing a new technique to help surgeons perform more precise robotic surgery for early-stage lung cancer. It uses a special fluorescent dye that makes healthy lung tissue glow green, helping the surgeon see and remove only the diseased segment while saving as much …

This study is testing a combination of chemotherapy and an immunotherapy drug (atezolizumab) for people with stage III non-small cell lung cancer. The goal is to see if this approach can delay the cancer from getting worse. After initial treatment, doctors will decide if surgery …

This is the first human study of an experimental drug called JANX008 for people with advanced solid tumors that have spread and stopped responding to standard treatments. The main goal is to find a safe dose and understand how the body handles the drug. Researchers will also look…

This large Phase 3 trial aims to determine if a new combination of two immunotherapy drugs (nivolumab + relatlimab) plus chemotherapy works better than the current standard treatment (pembrolizumab + chemotherapy) for people with advanced non-small cell lung cancer. The study wil…

This study is testing a new drug called FMC-376 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find a safe and effective dose and to see if the drug can shrink or control tumors. It is for patients whose cancer ha…

This study is testing if using a special protein test to guide treatment choices helps people with advanced lung cancer live longer without their cancer getting worse, compared to standard treatment selection. It will involve 56 adults with newly diagnosed, advanced non-small cel…

This study aims to collect information from routine medical practice to better understand the safety and effectiveness of two standard treatment options for advanced lung cancer with a specific genetic change (EGFR mutation). It will observe about 538 patients who are already rec…

This study tests a personalized treatment for advanced non-small cell lung cancer patients who have exhausted standard options. Doctors collect immune cells from a patient's tumor, grow billions of them in a lab, then infuse them back into the patient to attack the cancer. The tr…

This study is testing whether using a highly focused, high-dose radiation treatment on all visible tumor sites can help people with a limited number of cancer metastases live longer without their disease getting worse. It is for adults with breast cancer or non-small cell lung ca…

This study is testing a new drug called MCLA-129 in people with advanced cancers, including lung, head and neck, and colorectal cancer, that have progressed after standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The drug is design…

This early-stage study is testing the safety and initial effects of a new oral medicine, PF-07799544, when taken with another drug, PF-07799933. It is for adults with advanced solid tumors, like melanoma or lung cancer, that have a specific genetic change called a BRAF V600 mutat…

This early-stage study is testing a new radioactive drug called [177Lu]Lu-NNS309 in patients with advanced pancreatic, lung, breast, or colorectal cancers that have stopped responding to standard treatments. Researchers will first use a special imaging scan to see if patients' tu…

This study is testing an experimental drug called WSD0922-FU for people with advanced non-small cell lung cancer. It is for patients whose cancer has started growing again after initial treatment with the drug osimertinib and who have a specific genetic change (C797S mutation) in…

This is an early-stage study to check the safety and initial activity of an experimental drug called DR-0202. It is for adults with advanced cancers that have spread, returned, or stopped responding to at least two prior treatments. The main goal is to find a safe dose and see ho…

This study is testing a new oral medication called Dositinib for adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The main goals are to find a safe and effective dose and to see how well the drug controls the cancer. The study is…

This study is testing a new experimental drug called TUB-040 in people with advanced ovarian cancer or non-small cell lung cancer that has stopped responding to standard platinum-based treatments. The drug is designed to act like a 'smart bomb,' delivering a powerful chemotherapy…

This study aims to see if regularly checking pembrolizumab drug levels in the blood helps doctors use this lung cancer treatment more effectively. Researchers will follow 75 adults with non-small cell lung cancer who are already receiving pembrolizumab treatment. They'll monitor …

This large, late-stage study aims to see if adding a new investigational drug (BL-B01D1) to a standard targeted therapy (osimertinib) works better than the standard therapy alone for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation…

This study is testing whether a simple rectal mucus sample can detect lung, pancreatic, bladder, and colorectal cancers by looking for DNA changes. Researchers will collect samples from 450 people using a special swab device to see if cancer-related genetic markers appear in the …

This study is testing two new imaging methods to help doctors better see lung cancer tumors. Before surgery, patients get a special PET scan. During surgery, doctors use a fluorescent dye that makes tumor tissue glow under special light. The goal is to see if these methods can mo…

This study is testing a new type of PET scan to see if it can better detect and track the spread of non-small cell lung cancer, especially when it has reached the brain. Researchers will compare this new scan to standard imaging methods in about 20 patients. The goal is to see if…

This study is testing a new, non-invasive breath test called an 'electronic nose' to see if it can measure how well lung cancer treatment is working. Researchers will collect breath samples from 50 people with non-small cell lung cancer before and after their standard treatment. …

This study aims to understand which of two common, minimally invasive lung cancer surgeries leads to better recovery. Researchers will follow 180 patients with early-stage lung cancer for one year after their operation. They will compare how much shortness of breath patients expe…

This study is testing if a drug called nanocrystalline megestrol acetate can help people with advanced lung cancer keep their appetite and body weight up while they undergo combined chemotherapy and radiation. It compares the drug to a placebo (inactive pill) when both are given …

This study asks cancer patients which way they prefer to receive their immunotherapy drugs: as a quick injection under the skin or through a longer IV infusion. Researchers will enroll 480 people with various advanced cancers to compare comfort, convenience, and quality of life b…

This study is testing a new mobile app that guides lung cancer patients and their family caregivers through yoga exercises. The goal is to see if the app is easy to use and helpful for managing stress and improving quality of life during radiation treatment. Researchers will enro…

This study is comparing two ways to help patients recover after surgery for a common type of lung cancer. It will test if using a special breathing exercise app on a smartphone, in addition to standard in-person therapy, works better than the in-person therapy alone. The goal is …

This study is testing whether online singing classes can help people who have had surgery for non-small cell lung cancer. Many patients continue to experience symptoms like shortness of breath, fatigue, and reduced quality of life months after surgery, with limited support option…

This study is testing whether a 12-week phone and app-based exercise coaching program helps people walk more and improve their quality of life after surgery for non-small cell lung cancer. Researchers will enroll 90 patients who had surgery 1 to 12 months ago and randomly assign …

This study is testing if an 8-week pulmonary rehabilitation program can help people who have survived advanced non-small cell lung cancer. The program includes exercise training and education, aiming to reduce shortness of breath and fatigue while improving quality of life. Resea…

This study is testing whether a shared exercise program is practical and acceptable for patients with non-small cell lung cancer who are receiving radiation therapy and their family caregivers. It aims to see if the program can improve physical function and quality of life for bo…

This study aims to understand how lung cancer cells survive during the first weeks of targeted drug therapy. Researchers will take tumor samples and blood from 100 adults with specific genetic mutations before and after starting treatment. By comparing these samples, they hope to…

This study aims to create better comparison groups for future lung cancer research by tracking patients who are already receiving standard chemotherapy. It will follow 550 adults with advanced lung cancer that has spread, collecting data on how they respond to their current treat…

This study aims to find biological signs of aging that can help doctors better predict how older adults with lung cancer will respond to treatment. It will follow 385 patients aged 70+ to see if certain markers in their blood and tissues are linked to outcomes like unplanned hosp…

This study aims to see if growing a patient's own lung cancer cells in a lab dish can help doctors choose the most effective treatment for them. Researchers will test drugs on these lab-grown cell clusters and see if the results match how well the patient responds to the same dru…

This study aims to gather detailed, real-world information on how well the drug osimertinib works for people with advanced lung cancer that has a specific genetic change (EGFR mutation). It will follow about 130 patients who are starting this treatment, collecting data on their h…

This study collects blood, tissue, and other samples from adults with cancer or pre-cancerous conditions. The goal is to understand how cancer works and why treatments affect people differently. Researchers will bank these samples for future lab studies to help develop better imm…

This study is testing a new artificial intelligence (AI) tool designed to help match people with advanced cancer to suitable clinical trials. It will enroll up to 50,000 patients to see if using this AI system makes it easier for patients to find and join trials. The researchers …

This study is testing a new type of PET scan to see if it can better detect lung cancer and measure how it responds to immunotherapy. Six participants with non-small cell lung cancer who have not yet started treatment will receive the new imaging agent and undergo several scans b…

This study aims to find out if measuring a protein called Galectin-3 in the blood can help predict how patients with certain cancers will respond to immunotherapy drugs (PD-1/PD-L1 inhibitors). Researchers will observe 300 adults with kidney, lung, liver, or bladder cancer who ar…

This study aims to gather real-world information on how standard, approved lung cancer treatments work for patients aged 70 and older. It will follow 500 participants receiving their first treatment to see how long the treatment works, monitor side effects, and understand its imp…

This study aims to understand what matters most to patients and doctors when choosing first-line treatments for advanced lung cancer. Researchers will survey 590 Chinese patients and physicians who have experience with these treatments. The survey asks participants to make choice…

This study aims to collect tissue samples from adults with various lung and thymic cancers to better understand these diseases. Researchers will analyze blood, tumor, and other samples from up to 2000 participants to learn how these cancers develop and respond to treatment. The g…

This study aims to better understand the experience of cancer-related fatigue in people with non-small cell lung cancer who are receiving immunotherapy. Researchers will conduct two interviews with 20 patients to learn about how often fatigue occurs, how severe it is, and how it …

This study aims to learn if finding cancer cells or cancer DNA in a person's blood, urine, or bone marrow can help doctors better understand how cancer spreads. Researchers will collect samples from 100 people with cancer and 200 people at high risk for lung cancer to see if thes…

This study aims to understand why some people develop lung cancer at age 45 or younger, which is unusual. Researchers will collect blood, saliva, and tumor samples from 500 participants to look for genetic patterns and risk factors. The goal is to gather knowledge that could lead…

This study aims to understand if the types of bacteria in a person's gut are connected to how well their lung cancer treatment works and what side effects they experience. Researchers will collect stool samples from 82 adults with advanced lung cancer before they start treatment …

This study aims to understand why some lung cancers with a specific genetic change (ROS1 fusion) eventually stop responding to the targeted drug entrectinib. Researchers will analyze tissue and blood samples from patients who have taken entrectinib as part of their regular care. …

This study aims to find out if simple blood tests can predict how well patients with advanced cancers respond to immunotherapy drugs. Researchers will track 50 patients with late-stage lung, breast, colorectal, liver, or stomach cancer who are starting immunotherapy. They will co…

This study aims to collect tumor tissue and blood cells from people with advanced solid tumors to prepare for future CAR T-cell therapy. Researchers will analyze the cancer tissue to understand how tumors hide from the immune system and collect participants' own immune cells thro…

This study aims to understand how different cancers interact with the body's immune system, particularly focusing on immune cells called T cells. Researchers will collect tissue and blood samples from 1,100 patients with seven types of solid tumors over five years. The goal is to…

This study aims to understand how non-small cell lung cancer changes at a molecular level during standard treatment. It will follow 1,200 patients, collecting blood samples over time to see if tiny traces of cancer DNA in the blood can predict if the cancer will come back or how …